COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Aug 12, 2024 2:02pm

349 Views

Post# 36174950

Linkedin comment

There merger between AEterna Zentaris Inc. & Ceapro is now complete. This means exciting research & development programs will start to proceed, along with more products likely to go into commercialization!

About

As leader of our Canadian Science and Innovation Practice, I work with an innovative team developing and implementing talent and data driven strategies to ensure real estate supports the people that drive success.

My team advises clients across the research, life science, technology and nonprofit sectors. Many of our clients operate across these sectors (i.e. nonprofit with wet lab premises conducting important research) and require the specialized knowledge our team is proud to offer.

I have had the privilege to work with talented people at leading organizations including Centene Corporation, Think Research, Synaptive Medical, Deep Genomics, Assurance IQ, Ronald McDonald House, Plan International Canada, Unifor, and many others. Our diverse experience with occupiers in both the private and public sector provides an extensive foundation of knowledge from which we draw enabling us to deliver the highest level of service.

To learn more about our specialized service offering, please contact me at (416) 505.4687, or feel free to email me any time at matthew.johnson@colliers.com.

<< Previous

Bullboard Posts

Next >>

Grand Portage Resources pioneers new gold exploration in Alaska